The day in pharma, read in minutes.
NewsSight Sciences Receives FDA Clearance For OMNI Ultra Surgical System To Treat Glaucoma
Sight Sciences receives FDA clearance for its OMNI Ultra Surgical System, an implant-free MIGS device for treating open-angle glaucoma.
Editas Medicine Appoints Dr. Patrick Ellinor To Board Of Directors
IQVIA And Medera Partner To Advance Cardiac Gene Therapy And Human-Based Drug Discovery
Applied Biologics Begins AATB Reaccreditation Process To Maintain High Tissue Banking Standards
ClinNEXUS Appoints John Stamatopoulos As Chief Growth Officer To Drive Strategic Expansion
Latest news
11 storiesSilexion Therapeutics Reports New Preclinical Data Supporting SIL204 Combination With Immunotherapy In KRAS-Driven Cancers
Silexion Therapeutics reports new preclinical data showing SIL204 may boost immune response to KRAS-driven cancers, supporting checkpoint combos.
Capra Biosciences Secures Additional ASPR Funding To Expand Domestic API Manufacturing Program
Capra Biosciences secures additional ASPR funding, bringing total support to $17 million, to expand domestic manufacturing of critical APIs.
Amplia Therapeutics Signs Clinical Trial Collaboration With Eli Lilly To Study New Combination Therapy For Advanced Lung Cancer
Amplia Therapeutics partners with Eli Lilly on a Phase 1b/2b trial combining narmafotinib with olomorasib for advanced non-small cell lung cancer.
Basilea Secures Expanded BARDA Funding for Development of Ceftibuten-Ledaborbactam Etzadroxil, Advance Oral Antibiotic for Complicated UTIs
BARDA awarded Basilea an additional $5.4M to develop its oral antibiotic for complicated UTIs, bringing total funding for the program to $30.8M.
Veru Strengthens Weight Loss IP Portfolio with Patent Covering Enobosarm-Based Quality Weight Loss Therapy
Veru receives a USPTO Notice of Allowance for a patent covering enobosarm with semaglutide to improve weight-loss outcomes and preserve lean muscle mass.
Autonomix Medical Secures U.S. Patent For Precision Nerve-Targeted Cancer Treatment Technology
Autonomix secured a U.S. patent for catheter-based neural mapping technology designed to enable precision cancer treatment and targeted nerve modulation.
Rhythm Pharmaceuticals Reports Promising Phase 2 Results for Once-Weekly RM-718 in Acquired Hypothalamic Obesity
Rhythm's Phase 2 trial shows RM-718 reduced BMI by 11.6% in acquired hypothalamic obesity patients, with encouraging safety and tolerability results.
Aurobindo Pharma Posts 16.3% Revenue Growth to Rs 9,150 Crore in Q1 FY27
Aurobindo Pharma reports Rs 9,150 crore revenue in Q1 FY27, with EBITDA margin expanding 60 bps to 21.0% as injectable capacity investments gain traction.
Takeda Gains FDA Approval for Orzeyful as First Complete Narcolepsy Type 1 Treatment
FDA approves Takeda's Orzeyful for narcolepsy type 1, the first orexin receptor agonist; DEA scheduling decision required before commercial launch.
Biomea Fusion Advances Icovamenib-Semaglutide Combination Trial in Obesity Program
Biomea Fusion initiates icovamenib-semaglutide combination trial with University of Leicester, adding formulation complexity to an already multi-threaded obesity pipeline.
Victory Medical Center Pharmacy Recalls Compounded Glutathione Vials Across Three States Over Elevated Endotoxin Levels
Victory Medical Center Pharmacy recalls compounded glutathione vials over elevated endotoxin levels, with adverse events already reported across TX, FL, and NY.
Worth your time this week
Fresenius Kabi Recalls Morphine Sulfate Lot After Dilaudid Prefilled Syringe Labeling Mix-Up
FibroBiologics Secures European Patent for Sox9-Based Cartilage Regeneration Gene Therapy
Biocon Gains EMA Approval for Malaysian Insulin Fill-Finish Plant as U.S. Biosimilar Launches Accelerate
